HIV Disease Among Substance Users: Treatment Issues

Global HIV/AIDS Medicine

Volumn , Issue , 2007, Pages 513-526

  Bruce, R Douglas ^a   Altice, Frederick L ^a   Friedland, Gerald ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78449301036     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-2882-6.50048-4     Document Type: Chapter

References (76)

1. UNAIDS (2002) Report on the Global HIV/AIDS Epidemic Geneva: UNAIDS
2. Anonymous (1990) Risk behaviors for HIV transmission among intravenous-drug users not in drug treatment-United States, 1987–1989. MMWR 39 273-276.
3. N Abdala, JM Carney, AJ Durante, et al. (October 2003) Estimating the prevalence of syringe-borne and sexually transmitted diseases among injection drug users in St Petersburg, Russia. Int J Std AIDS 14 697-703.
4. JA Kelly and YA Amirkhanian (June 2003) The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. Int J Std AIDS 14 361-371.
5. A Saelim, A Geater, V Chongsuvivatwong, et al. (1998) Needle sharing and high-risk sexual behaviors among IV drug users in Southern Thailand. AIDS Patient Care St 12 707-713.
6. WT Caiaffa, FA Proietti, AB Carneiro-Proietti, et al. (2003) Epidemiological Study of Injection Drug Users in Brazil (AjUDE-Brasil Project). The dynamics of the human immunodeficiency virus epidemics in the south of Brazil: increasing role of injection drug users. Clin Infect Dis 37(Suppl), 376-381.
7. C Zhang, R Yang, X Xia, et al. (2002) High prevalence of HIV-1 and hepatitis C virus coinfection among injection drug users in the southeastern region of Yunnan, China. J Acquir Immune Defic Syndr 29 191-196.
8. World Health Organization, United Nations Office on Drugs and Crime, UNAIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. World Health Organization, United Nations Office on Drugs and Crime, UNAIDS; 2004.
9. T Kerr, A Wodak, R Elliott, et al. (2004) Opioid substitution and HIV/AIDS treatment and prevention. Lancet 364 1918-1919.
10. CM Doran, M Shanahan, RP Mattick, et al. (2003) Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 71 295-302.
11. P Alcabes and GH Friedland (1995) Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 20 1467-1479.
12. MS Dworkin and JM Williamson (2003) Adult/Adolescent Spectrum of HIV Disease Project. AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 33 267-273.
13. A Mocroft, B Ledergerber, C Katlama, et al. (2003) EuroSIDA study group. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362 22-29.
14. KA Gebo, M Diener-West and RD Moore (2001) Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27 143-152.
15. AH Anis, D Guh, RS Hogg, et al. (2000) The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 18 393-404.
16. LC van Asten, F Boufassa, V Schiffer, et al. (2003) Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population level. Eur J Public Health 13 347-349.
17. AH Kaplan, A Scheyett and CE Golin (2005) HIV and stigma: analysis and research program. Curr HIV/AIDS Rep 2 184-188.
18. P Mateu-Gelabert, C Maslow, PL Flom, et al. (2005) Keeping it together: stigma, response, and perception of risk in relationships between drug injectors and crack smokers, and other community residents. AIDS Care 17 802-813.
19. A Palepu, B Yip, C Miller, et al. (2001) Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS 15 423-424.
20. GH Friedland (1998) AIDS and compassion. JAMA 259 2898-2899.
21. JC Ball and A Ross (1991) The effectiveness of methadone maintenance treatment New York: Springer-Verlag
22. FL Altice, S Springer, M Buitrago, et al. (2003) Pilot study to enhance HIV care using needle exchange-based health services for out-of-treatment injecting drug users. J Urban Health 80 416-427.
23. FL Altice, JA Mezger, J Hodges, et al. (2004) Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clin Infect Dis 38(Suppl), 376-387.
24. AS Thompson, KM Blankenship, PA Selwyn, et al. (1998) Evaluation of an innovative program to address the health and social service needs of drug-using women with or at risk for HIV infection. J Community Health 23 419-440.
25. SA Springer, E Pesanti, J Hodges, et al. (2004) Effectiveness of antiretroviral therapy among HIV-infected prisoners: re incarceration and the lack of sustained benefit after release to the community. Clin Infect Dis 38 1754-1760.
26. S Basu, RD Bruce, D Barry and FL Altice (2007) Pharmacological pain control for HIV-infected adults with a history of drug dependence. J Subs Abuse Treat in press.
27. FL Altice, LE Sullivan, D Smith-Rohrberg, et al. (2006) The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin Infect Dis 43(Suppl 4), S178-S183.
28. S Basu, D Smith-Rohrberg, RD Bruce, et al. (2006) Models for integrating buprenorphine therapy into HIV care. Clin Infect Dis 42 716-721.
29. A Urbina and K Jones (2004) Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 38 890-894.
30. D Smith-Rohrberg, RD Bruce and FL Altice (2004) Review of corrections based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues 34 451-480.
31. K Dolan, W Hall and A Wodak (1996) Methadone maintenance reduces injecting in prison. Br Med J 312 1162.
32. EC Donny, SL Walsh, GE Bigelow, et al. (2002) High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology (Berl) 161 202-212.
33. PJ Fudala, TP Bridge, S Herbert, et al. (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349 949-958.
34. JB Murray (1998) Effectiveness of methadone maintenance for heroin addiction. Psychol Rep 83 295-302.
35. DS Metzger, GE Woody, AT McLellan, et al. (1998) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6 1049-1056.
36. RE Johnson, MA Chutuape, EC Strain, et al. (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343 1290-1297.
37. DA Fiellin and PG O'Connor (2002) Clinical practice. Office-based treatment of opioid-dependent patients. N Engl J Med 347 817-823.
38. A Liguori, WH Morse and J Bergman (1996) Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277 462-472.
39. N Clark, N Lintzeris, A Gijsbers, et al. (2002) LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev (2), CDO02210.
40. RE Johnson, T Eissenberg, ML Stitzer, et al. (1995) Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40 27-35.
41. RD Bruce, S Dvoryak, L Sylla and FL Altice (2007) HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine - program description and policy implicaitons. Int J Drug Pol in press.
42. RA Greenstein, BD Evans, AT McLellan, et al. (1983) Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend 12 173-180.
43. A Roth, I Hogan and C Farren (1997) Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat 14 19-22.
44. JA Peck, CJ Reback, X Yang, et al. (2005) Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 82 ilOO-il08
45. SC Kalichman and D Rompa (2003) HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Trans Infect 79 59-61.
46. RD Bruce and FL Altice (2003) Editorial comment: why treat three conditions when it is one patient? AIDS Read 13 378-379.
47. S Basu, LA Chwastiak and RD Bruce (2005) Clinical management of depression and anxiety in HIV-infected adults. AIDS 19 2057-2067.
48. Anonymous (2003) Treating 3 million by 2005: making it happen: the WHO Strategy: the WHO an UNAIDS global initiative to provide antiretroviral therapy to 3 million people with HIV/AIDS in developing countries by the end of 2005 Geneva: World Health Organization
49. RD Bruce, FL Altice, MN Gourevitch and GH Friedland (2006) Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 41 563-572.
50. EF McCance Katz, PM Rainey, GH Friedland, et al. (2001) Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 10 296-307.
51. Sellers E, Lam R, McDowell J, et al. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following co-administration: CNAA1012. Abstract No. 305. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA: 26-29 September 1999.
52. Smith P, Kearney B, Cloen D, et al. Tenofovir DF does not affect the pharmacokinetics or pharmacodynamics of methadone. Abstract no. 869. 2nd IAS Conference on HIV Pathogenesis and Treatment, Paris, France: July 2003.
53. Friedland G, Rainey P, Jatlow P, et al. pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. 14th International AIDS Conference: 7-12 July 2002.
54. FL Altice, GH Friedland and EL Cooney (1999) Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13 957-962.
55. SM Clarke, FM Mulcahy, J Tjia, et al. (2001) The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51 213-217.
56. McCance Katz E, Pade P, Friedland G, et al. Efavirenz is not associated with opiate withdrawal in buprenorphine-maintained individuals. 12th Conference on Retroviruses and Opportunistic Infections: February 2005.
57. McCance Katz EF. Antiretroviral therapy in injection drug users with HIV disease: using drug interactions to design more effective treatment. Presented at the 3rd International Workshop on Clinical Pharmacology of HIV Therapy, Washington, DC: April 2002.
58. EF McCance-Katz, DE Moody, GD Morse, et al. (2006) Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin Infect Dis 43(Suppl 4), S224-S234.
59. EF McCance Katz, PM Rainey, G Friedland, et al. (2003) The protease inhibitor lopinavir-ritonavir may produce opiate withdrawal in methadone-maintained patients. Clin Infect Dis 37 476-482.
60. L Cantilena, J McCrea, D Blazes, et al. (1999) Lack of pharmacokinetic interaction between indinavir and methadone (Abstract PI-74). Clin Pharmacol Ther 65 135.
61. Hsyu PH, Lillibridge JH, Maroldo L, et al. Pharmacokinetic(PK) and pharmacodynamic (PD) interactions between nelfinavir and methadone. Abstract No. 87 or 245. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA: 30 Jan-2 Feb 2000.
62. GlaxoSmithKline Product Information. Agenerase(r), amprenavir. GlaxoSmithKline, Research, Triangle Park, NC (revised September 2002).
63. Friedland GH, Andrews L, Argawala S, et al. Lack of an effect of Atazanavir on steady-state pharmacokinetics of methadone in chronically treated subjects. International Symposium on HIV and Emerging Infectious Disease, Toulon, France: June 2004.
64. JG Gerber, S Rosenkranz, Y Segal, et al. (2001) ACTG 401 Study Team. Effect of ritonavir/saquinavir on stereoselective pharmacokinetics of methadone: results of AIDS Clinical Trials Group (ACTG) 401. J Acquir Immune Defic Syndr 27 153-160.
65. MJ Shelton, D Cloen, R DiFrancesco, et al. (2004) The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone. J Clin Pharmacol 44 293-304.
66. S Clarke, F Mulcahy, C Bergin, et al. (2002) Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 34 1143-1145.
67. Boehringer Ingelheim Pharmaceuticals Inc. Product information: Aptivus(r), tipranavir. Boehringer Ingelheim Pharmaceuticals Inc. Rigdefield, CT (PI revised June 2005).
68. RD Bruce and FL Altice (2006) Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20 783-784.
69. E McCance-Katz, P Pade, GD Morse, et al. (2006) Interaction between buprenorphine and atazanavir (oral abstract). Program and Abstracts of the 68* Annual Meeting of the College on Problems of Drug Dependence (Phoenix) Philadelphia: College on Problems of Drug Dependence 44.
70. EF McCance-Katz, DE Moody, PF Smith, et al. (2006) Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin Infect Dis 43(Suppl 4), S235-S246.
71. MJ Kreek, JW Garfield, CL Gutjahr, et al. (1976) Rifampin induced methadone withdrawal. N Engl J Med 1976 1104-1106.
72. MN Cobb, J Desai, LS Brown, et al. (1998) The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharm Ther 63 655-662.
73. RS Broadhead and FL Altice (2002) Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. J Drug Issues 32 329-356.
74. RS Broadhead, C Borch, Y van Hulst, et al. (2003) Safer injection sites in New York City: A utilization survey of injection drug users. J Drug Issues 33 533-538.
75. CDC. Compendium of HIV Prevention Interventions with Evidence of Effectiveness. Centers for Disease Control & Prevention. National Center or HIV, STD, and TB Prevention; 2001.
76. H Pollack, K Khoshnood, K Blankenship, et al. (2002) The impact of needle exchange-based health services on emergency department use. J Gen Int Med 17 341-348.